Emergent Biosolutions Inc. Stock
We can see a decrease in the price for Emergent Biosolutions Inc.. Compared to yesterday it has lost -€0.205 (-2.820%).
With 6 Buy predictions and not the single Sell prediction the community is currently very high on Emergent Biosolutions Inc..
As a result the target price of 12 € shows a very positive potential of 71.55% compared to the current price of 7.0 € for Emergent Biosolutions Inc..
For the coming years our community has positive and negative things to say abot the Emergent Biosolutions Inc. stock. Criterium "Company culture" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.
Pros and Cons of Emergent Biosolutions Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
S********** s********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Emergent Biosolutions Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Emergent Biosolutions Inc. | -2.820% | -11.343% | -9.684% | 32.131% | -32.676% | -5.217% | -86.792% |
| Ligand Pharmaceuticals | 2.970% | 1.980% | 3.518% | 126.374% | 24.096% | 209.774% | 122.270% |
| United Therapeutics | -0.420% | -1.202% | -2.594% | 70.504% | 11.608% | 133.431% | 228.897% |
| Ionis Pharmaceuticals Inc. | -0.930% | -1.464% | 0.466% | 109.737% | -4.915% | 63.761% | 127.696% |
Comments
Emergent Biosolutions (EBS) had its "buy" rating reaffirmed by Benchmark Co..
Show more
Ratings data for EBS provided by MarketBeat
Emergent Biosolutions (EBS) had its "buy" rating reaffirmed by UBS Group AG.
Show more
Ratings data for EBS provided by MarketBeat
Emergent Biosolutions (NYSE:EBS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Show more
Ratings data for EBS provided by MarketBeat